Table 3.
Proportion of patients with LDAS* or remission at baseline and at Month 6 for second line abatacept stratified by 1 or ≥2 prior anti-TNF agent
|
Measure |
Remission at month 6 |
LDAS* at month 6 |
||
|---|---|---|---|---|
| N | Percent (95% CI) | N | Percent (95% CI) | |
| |
|
One previous anti-TNF |
|
|
|
DAS28 (ESR) |
245 |
15.9 (11.3, 20.5) |
245 |
29.8 (24.1, 35.5) |
|
DAS28 (CRP) |
57 |
22.8 (11.9, 33.7) |
57 |
42.1 (29.3, 54.9) |
|
CDAI |
289 |
5.2 (2.6, 7.7) |
289 |
35.6 (30.1, 41.2) |
| |
|
≥2 previous anti-TNFs |
|
|
|
DAS28 (ESR) |
234 |
12.8 (8.5, 17.1) |
234 |
25.6 (20.0, 31.2) |
|
DAS28 (CRP) |
75 |
17.3 (8.8, 25.9) |
75 |
33.3 (22.7, 44.0) |
| CDAI | 286 | 4.9 (2.4, 7.4) | 286 | 28.3 (23.1, 33.5) |
*LDAS includes patients in remission (DAS remission: <2.6; CDAI remission: ≤2.8).
CDAI, Clinical Disease Activity Index; DAS, Disease Activity Score; LDAS, Low Disease Activity Score (≤3.2 for DAS and ≤10 for CDAI).